| High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial BH Grønberg, KT Killingberg, Ø Fløtten, OT Brustugun, K Hornslien, ... The Lancet Oncology 22 (3), 321-331, 2021 | 92 | 2021 |
| Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer BH Grønberg, TO Halvorsen, Ø Fløtten, OT Brustugun, PF Brunsvig, ... Acta Oncologica 55 (5), 591-597, 2016 | 77 | 2016 |
| Frailty modelling of testicular cancer incidence using Scandinavian data TA Moger, OO Aalen, TO Halvorsen, HH Storm, S Tretli Biostatistics 5 (1), 1-14, 2004 | 37 | 2004 |
| Comorbidity and outcomes of concurrent chemo-and radiotherapy in limited disease small cell lung cancer TO Halvorsen, S Sundstrøm, Ø Fløtten, OT Brustugun, P Brunsvig, ... Acta Oncologica 55 (11), 1349-1354, 2016 | 23 | 2016 |
| The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study SGF Wahl, HY Dai, EF Emdal, T Berg, TO Halvorsen, AL Ottestad, ... Cancers 13 (17), 4294, 2021 | 15 | 2021 |
| Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer TO Halvorsen, M Herje, N Levin, RM Bremnes, OT Brustugun, Ø Fløtten, ... Lung Cancer 102, 9-14, 2016 | 15 | 2016 |
| Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer TO Halvorsen, CD Valan, M Slaaen, BH Grønberg Journal of Cachexia, Sarcopenia and Muscle 11 (5), 1283-1290, 2020 | 12 | 2020 |
| Fragmentation assessment of FFPE DNA helps in evaluating NGS library complexity and interpretation of NGS results AL Ottestad, EF Emdal, BH Grønberg, TO Halvorsen, HY Dai Experimental and Molecular Pathology 126, 104771, 2022 | 11 | 2022 |
| Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). BH Gronberg, KT Killingberg, Ø Fløtten, MM Bjaanæs, T Madebo, ... Journal of Clinical Oncology 38 (15_suppl), 9007-9007, 2020 | 11 | 2020 |
| Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy SGF Wahl, HY Dai, EF Emdal, AL Ottestad, VG Dale, E Richardsen, ... The Journal of Pathology: Clinical Research 7 (3), 209-219, 2021 | 10 | 2021 |
| Development of EirV3: a computer-based tool for patient-reported outcome measures in cancer H Krogstad, C Brunelli, K Sand, E Andersen, H Garresori, T Halvorsen, ... JCO clinical cancer informatics 1, 1-14, 2017 | 10 | 2017 |
| Timing of severe toxicity from chemotherapy in patients with lung cancer K Sjøgren, KA Jacobsen, BH Grønberg, TO Halvorsen Anticancer research 40 (11), 6399-6406, 2020 | 8 | 2020 |
| Survival in limited disease small cell lung cancer according to N3 lymph node involvement CD Valan, JE Slagsvold, TO Halvorsen, M Herje, RM Bremnes, ... Anticancer research 38 (2), 871-876, 2018 | 7 | 2018 |
| Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC TO Halvorsen, K Stokke, KT Killingberg, SX Raj, S Sørhaug, ... Acta Oncologica 59 (9), 1051-1057, 2020 | 6 | 2020 |
| Thoracic Radiotherapy in Limited-Stage SCLC—a Population-Based Study of Patterns of Care in Norway From 2000 Until 2018 G Graabak, BH Grønberg, MS Sandvei, Y Nilssen, TO Halvorsen JTO Clinical and Research Reports 3 (2), 100270, 2022 | 5 | 2022 |
| Associations between severe co‐morbidity and muscle measures in advanced non‐small cell lung cancer patients BH Grønberg, CD Valan, T Halvorsen, B Sjøblom, MS Jordhøy Journal of Cachexia, Sarcopenia and Muscle 10 (6), 1347-1355, 2019 | 5 | 2019 |
| Prognostic value of post first-line chemotherapy glasgow prognostic score in advanced non-small cell lung cancer K Stokke, MS Sandvei, BH Grønberg, M Slaaen, KT Killingberg, ... Clinical Medicine Insights: Oncology 16, 11795549221086578, 2022 | 4 | 2022 |
| Randomized phase II trial comparing two schedules of thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). BH Grønberg, TO Halvorsen, Ø Fløtten, OT Brustugun, P Brunsvig, ... Journal of Clinical Oncology 30 (15_suppl), 7027-7027, 2012 | 4 | 2012 |
| Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial H Horndalsveen, TN Alver, AM Dalsgaard, LV Rogg, N Helbekkmo, ... Molecular Oncology 17 (3), 487-498, 2023 | 3 | 2023 |
| Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18F-FDG PET/CT in early-stage non-small cell lung cancer AL Ottestad, H Johansen, TO Halvorsen, HY Dai, SGF Wahl, EF Emdal, ... BMC cancer 23 (1), 646, 2023 | 2 | 2023 |
Seppo W. LangerAss. Professor, MD, PhD, Rigshospitalet and University of Copenhagen在 regionh.dk 的电子邮件经过验证
